In brief
The type-2-diabetes companion to the obesity trial. Adults with HbA1c between 7 and 10.5 percent and a body-mass index of 25 to 50, on diet and exercise or stable metformin, were assigned to weekly placebo, dulaglutide at 1.5 milligrams, or retatrutide at maintenance doses from 0.5 to 12 milligrams. At 24 weeks HbA1c fell by 0.43 to 2.02 percentage points across the retatrutide doses against 0.01 on placebo and 1.41 on dulaglutide; all doses above 0.5 milligrams beat placebo and the two highest beat dulaglutide. By 36 weeks weight had fallen 3.2 to 16.9 percent with retatrutide against 3.0 percent on placebo and 2.0 percent on dulaglutide. Mild-to-moderate gastrointestinal events affected 35 percent of retatrutide patients, the same proportion as on dulaglutide and against 13 percent on placebo. There was no severe hypoglycaemia and no deaths. Funded by Eli Lilly.
Study design
Phase-2, double-blind, double-dummy trial at 42 US centres: 281 adults with type 2 diabetes randomised to placebo, dulaglutide 1.5 mg or retatrutide at five maintenance doses, 36 weeks.
What it does not show
A dose-finding phase-2 study whose stated purpose was to pick doses for phase 3. Sponsor-funded, 36 weeks, and the participants had diabetes; it describes the pharmaceutical peptide only.
A clinical trial tests a pharmaceutical form of a compound, in a defined patient group, under medical supervision, with a defined endpoint. None of that transfers to a research-grade vial, and this page does not suggest it does.
Where this paper is cited
- Retatrutide — Phase 2 in type 2 diabetes, 36 weeks: HbA1c fell by up to about two percentage points and body weight by up to about 17% at the highest dose.
Other papers cited for Retatrutide
- Study in humans Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial Jastreboff et al. (2023), N Engl J Med
- Study in humans LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Coskun et al. (2022), Cell Metab
Further reading
- Research library: every paper cited on this site, by compound and by study type.
- GLP-1 family comparison
- How to read a certificate of analysis
- Lyophilised peptide storage and stability
How this page was made: the citation was retrieved from PubMed by PMID and checked against the title on the product page; the summary was written from the paper's abstract and reports only what the abstract reports. Read the paper itself before relying on any figure here.